Topics
chronic kidney diseaseDisease
anemiaDisease
Background: Previous meta-analyses suggest that treatment with erythropoiesis-stimulating agents (ESAs) in chronic kidney disease (CKD) increases the risk for death. Additional randomized trials have been recently completed. Purpose: To summarize the effects of ESA treatment on clinical outcomes in patients with anemia and CKD
Anaemia is a risk factor for death, adverse cardiovascular outcomes and poor quality of life in pati...
Anaemia is a risk factor for death, adverse cardiovascular outcomes and poor quality of life in pati...
Abstract Background A combination of safety concerns and labeling changes impacted use of erythropoi...
<b><i>Background:</i></b> The effect of anemia correction on kidney function in chronic kidney disea...
Background: Erythropoiesis stimulating agents (ESAs) were proposed to enhance survival of renal tiss...
Abstract Background Erythropoi...
Since the pioneering studies by Eschbach et al in 1987, erythropoiesis-stimulating agents (ESAs) hav...
Since the pioneering studies by Eschbach et al in 1987, erythropoiesis-stimulating agents (ESAs) hav...
Despite the widespread use of erythropoiesis-stimulating agents (ESAs) to treat anaemia, the risk of...
Erythropoiesis Stimulating Agents (ESAs) are well-tolerated and effective drugs for the treatment of...
Anemia is common in patients with cancer or with chronic kidney disease (CKD). Although the introduc...
BackgroundIn recent years, various studies have been conducted to investigate the relationship betwe...
BackgroundIn recent years, various studies have been conducted to investigate the relationship betwe...
BackgroundSeveral erythropoiesis-stimulating agents (ESAs) are available for treating anaemia in peo...
BackgroundSeveral erythropoiesis-stimulating agents (ESAs) are available for treating anaemia in peo...
Anaemia is a risk factor for death, adverse cardiovascular outcomes and poor quality of life in pati...
Anaemia is a risk factor for death, adverse cardiovascular outcomes and poor quality of life in pati...
Abstract Background A combination of safety concerns and labeling changes impacted use of erythropoi...
<b><i>Background:</i></b> The effect of anemia correction on kidney function in chronic kidney disea...
Background: Erythropoiesis stimulating agents (ESAs) were proposed to enhance survival of renal tiss...
Abstract Background Erythropoi...
Since the pioneering studies by Eschbach et al in 1987, erythropoiesis-stimulating agents (ESAs) hav...
Since the pioneering studies by Eschbach et al in 1987, erythropoiesis-stimulating agents (ESAs) hav...
Despite the widespread use of erythropoiesis-stimulating agents (ESAs) to treat anaemia, the risk of...
Erythropoiesis Stimulating Agents (ESAs) are well-tolerated and effective drugs for the treatment of...
Anemia is common in patients with cancer or with chronic kidney disease (CKD). Although the introduc...
BackgroundIn recent years, various studies have been conducted to investigate the relationship betwe...
BackgroundIn recent years, various studies have been conducted to investigate the relationship betwe...
BackgroundSeveral erythropoiesis-stimulating agents (ESAs) are available for treating anaemia in peo...
BackgroundSeveral erythropoiesis-stimulating agents (ESAs) are available for treating anaemia in peo...
Anaemia is a risk factor for death, adverse cardiovascular outcomes and poor quality of life in pati...
Anaemia is a risk factor for death, adverse cardiovascular outcomes and poor quality of life in pati...
Abstract Background A combination of safety concerns and labeling changes impacted use of erythropoi...
Add to ORKG